Femasys inc. announces enrollment is over 25% complete for femaseed® de novo trial following updated strategic study design

--femaseed de novo trial enrollment has accelerated with trial recruitment focus on male factor infertility-- --femaseed de novo trial enrollment has accelerated with trial recruitment focus on male factor infertility--
FEMY Ratings Summary
FEMY Quant Ranking